Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of radiolabeled orteronel in healthy male volunteers
NL-OMON36117Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orteronel in prostate cancer (PCa), sponsored by Takeda. Primary endpoints: Mass balance profile of orteronel, Pharmacokinetic profile of total radioactivity and orteronel/metabolites and 1 more. Started Apr 2011; status: active, not recruiting.
02
Drugs
orteronel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON36117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36117.